What Is Patient Experience Data? The Regulatory Perspective

Published May 21, 2018
Defining Patient Experience Data in Light of the US 21st Century Cures Act Baltimore, MD, USA—May 21, 2018—ISPOR, the professional society for health economics and outcomes research, held a session, “What Is Patient Experience Data? The Regulatory Perspective [W2],” this morning at ISPOR 2018 in Baltimore, MD, USA. This session was led by speakers from a variety of divisions at the US Food and Drug Administration (FDA) in Sliver Spring, MD, USA:
  • Martin Ho, MS, Center for Devices and Radiological Health (CDRH)
  • Megan Moncur, MS, Center for Biologics Evaluation and Research (CBER)
  • Pujita Vaidya, MPH, Office of Strategic Programs/Office of Program and Strategic Analysis, Center for Drug Evaluation and Research (CDER)
Over the past 5 years, the US FDA has made strides toward incorporating the “patient voice” in medical product decision-making. The Patient-Focused Drug Development and Patient Preference initiatives, begun under the FDA Safety and Innovation Act (FDASIA) of 2012, led to 24 public meetings held to learn from patients about their disease experience and to produce a guidance document about patient preference information in medical device applications. The 21st Century Cures Act and other FDA initiatives have helped to solidify the objectives of these initiatives. The speakers discussed current efforts to promote and advance the incorporation of patient input into the regulatory decision making processes. Providing examples of patient experience data and its application in medical product development, they identified opportunities for patient stakeholders to help strengthen capacity and advance fit-for-purpose methods and tools. Additional information on ISPOR 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBaltimore.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

ISPOR Chief Science Officer Dr Laura Pizzi Named to NJBIZ's 2026 People to Watch in Healthcare List

Jul 29, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) is proud to announce its Chief Science Officer, Laura Pizzi, PharmD, MPH, has been recognized by NJBIZ as one of its 2026 People to Watch in Healthcare.

ISPOR Publishes White Paper Focused on Systemic Coherence for Healthcare Decision Making in Europe

Jul 21, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has released a new white paper, “Achieving Systemic Coherence for Healthcare Decision Making in Europe.”

ISPOR Announces the Healthcare Investment Summit 2026

Jul 20, 2026

ISPOR announced their inaugural Healthcare Investment Summit 2026, which will bring together healthcare investors, founders, pharma and device executives, policy experts, health economists, and access leaders on September 22–23, 2026, in San Francisco to examine the critical factors shaping investment decisions across the healthcare landscape.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×